In our study, after the NLX treatment, we did not observe changes in hepatic steatosis in the histological examination; however, at the molecular level, we observed a significant decrease in Fabp4 mRNA expression in the livers of the ApoE−/− mice (fold change 0.8). This evidence concerns the gene FABP4 and fatty liver disease.